PREDICTORS FOR DOSE REDUCTION CAUSED BY HEMATOLOGICAL ADVERSE EVENTS IN PATIENTS WITH ADVANCED FIBROSIS RECEIVING PEGYLATED INTERFERON PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C: A SYSTEMATIC REVIEW AND META-REGRESSION ANALYSIS
COST-EFFECTIVENESS OF IMAGE-BASED SCREENING METHODS FOR HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS: A SYSTEMATIC REVIEW
N-6 THE HEPATITIS C DRUG PIPELINE: COLLABORATION BETWEEN ACADEMIC AND HTA AGENCY PARTNERS TO DEVELOP AN EARLY ECONOMIC MODEL
COST-EFFECTIVENESS OF IMAGE-BASED SCREENING METHODS FOR HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS: A SYSTEMATIC REVIEW
N-6 THE HEPATITIS C DRUG PIPELINE: COLLABORATION BETWEEN ACADEMIC AND HTA AGENCY PARTNERS TO DEVELOP AN EARLY ECONOMIC MODEL